Thursday, April 20, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 8:30</td>
<td>The value of Comprehensive Genomic Profiling, Including Immunotherapy &amp; Liquid Biopsy Options, Non-CME Breakfast Session, Allison W. Welsh, PhD</td>
</tr>
<tr>
<td></td>
<td>Moderators: Kashani-Sabet/Kim, Sponsored by Foundation Medicine, Inc.</td>
</tr>
<tr>
<td>8:35</td>
<td>Symposium C0-Chairs, Stanley, P.L. Leong, MD, FACS and Jonathan S. Zager, MD, will give the opening remarks and it is expected that the Mayor of San Francisco and Dr. Warren Browner, CEO of the California Pacific Medical Center will make a formal welcome to the Symposium Participants.</td>
</tr>
<tr>
<td>8:45</td>
<td>Donald Morton Surgical Oncology Memorial Lecture: Clinical Utility of Sentinel Lymph Nodes (KEYNOTE), Charles M. Balch, MD</td>
</tr>
<tr>
<td>9:15 - 10:25</td>
<td>Tumor Microenvironment in Cancer Initiation and Progression, Co-Chairs: Leong/Aktips</td>
</tr>
<tr>
<td>9:15</td>
<td>Interactions between Cancer and Stromal Cells: Selection of the Fittest Clone to Metastasize, Stanley P.L. Leong, MD</td>
</tr>
<tr>
<td>9:35</td>
<td>Social Evolution and Natural Selection as Applied to Cancer Progression, Athena Aktipis, PhD</td>
</tr>
<tr>
<td>9:55</td>
<td>Understanding Cancer Evolution and Progression by Mathematical Computation, Carlo C. Maley, PhD</td>
</tr>
<tr>
<td>10:15</td>
<td>Q&amp;A Panel Discussion</td>
</tr>
<tr>
<td>10:25 - 10:55</td>
<td>Coffee Break - Visit the Exhibit &amp; e-Posters - Networking</td>
</tr>
<tr>
<td>11:00 - 12:35</td>
<td>Tumor Growth and Metastatic Spread, Co-Chairs: McDonald/Witte</td>
</tr>
<tr>
<td>11:00</td>
<td>Cancer Metastasis and the Lymphatic System, Marlys H. Witte, MD</td>
</tr>
<tr>
<td>11:20</td>
<td>Plasticity of Lymphatics in Cancer and Inflammation, Donald M. McDonald, MD, PhD</td>
</tr>
<tr>
<td>11:40</td>
<td>Angiogenesis &amp; Lymphangiogenesis in Cancer Metastasis: Concordant or Independent, Michael Dellinger, PhD</td>
</tr>
<tr>
<td>12:00</td>
<td>Molecular Biomarkers for Cancer, Mohammed Kashani-Sabet, MD</td>
</tr>
<tr>
<td>12:20</td>
<td>Q&amp;A Panel Discussion</td>
</tr>
<tr>
<td>12:35 - 13:45</td>
<td>Prognostic Biomarkers in Malignant Melanoma, Non-CME Lunch Session Moderator: Jonathan Zager, Sponsored by CastleBioscience</td>
</tr>
<tr>
<td>12:35</td>
<td>Tissue Based Biomarkers of Prognosis in Malignant Melanoma, Jane L. Messina, MD, Moffitt Cancer Center, Tampa, USA</td>
</tr>
<tr>
<td>12:55</td>
<td>Surgical Management Implications of Prognostic Biomarkers in Melanoma, Eddy Hsueh, MD, Professor in the Department of Surgery, Division of General Surgery, at Saint Louis University School of Medicine, St. Louis, USA</td>
</tr>
<tr>
<td>13:15</td>
<td>Prognostic Biomarkers in the Era of Melanoma Immunotherapy, Jason J. Luke, MD - The University of Chicago Medicine, Chicago, USA</td>
</tr>
<tr>
<td>13:35</td>
<td>Q&amp;A Panel Discussion</td>
</tr>
<tr>
<td>13:50 - 15:10</td>
<td>Biomarkers for Cancer Metastasis Co-Chairs: Hoon/ Witz</td>
</tr>
<tr>
<td>13:50</td>
<td>Genomics for Cancer Metastasis, Marcus W. Bosenberg, MD, PhD</td>
</tr>
<tr>
<td>14:10</td>
<td>Utility of Circulating Tumor Cells/DNA to Detect Clinical Metastasis, David S.B. Hoon, PhD</td>
</tr>
<tr>
<td>14:30</td>
<td>Tumor Associated and Microenvironmental Drivers of Melanoma Brain Metastasis, Issac P. Witz, PhD</td>
</tr>
<tr>
<td>14:50</td>
<td>Q&amp;A Panel Discussion</td>
</tr>
</tbody>
</table>
Thursday, April 20, 2017 continued:

15:10 - 15:40  Coffee Break - Visit the Exhibit & e-Posters - Networking

15:45  Super Resolution Microscopy to study Molecules within a Cell (KEYNOTE), Nobel Laureate W.E. Moerner, PhD

16:15 - 17:50  Sentinel Lymph Node: Incubator or Marker for Cancer Metastasis?  
Session Chairs: Han/Reintgen

16:15  Sentinel Lymph Nodes Represent an Incubator for Metastasis, Mark B. Faries, MD
16:35  Sentinel Lymph Nodes Represent a Marker for Metastasis, Dale Han, MD
16:55  Nodal Staging, Survival and the Need for CLND with the SLN Procedure, Douglas S. Reintgen, MD
17:15  Role of Sentinel Lymph Node Staging in Melanoma Clinical Trials, Corrado Caracò, PhD
17:35  Q&A Panel Discussion

17:50 - 19:30  Poster Session, Non-CME, Poster Reception, Visit the Exhibits, Networking

Friday, April 21, 2017

7:30 - 8:30  Clinical Considerations for Treatment in Advanced Melanoma Non-CME Breakfast Session Sponsored by Amgen, Speaker: Jonathan Zager, Sponsored by Amgen

8:35 - 10:35  Henry Ford Health System Breast Cancer Metastasis to the Regional Lymph Nodes and Beyond - Mini-Symposium, Session Chairs: Nathanson/Pockaj

8:35  Introduction. S. David Nathanson, MD, Henry Ford Cancer Center, Detroit, USA
8:45  Lymph Nodes as Distribution Hubs for Systemic Metastasis of Breast Cancer, Dotscho Kerjaschki, MD
9:05  What Have We Learned from the Breast Cancer Sentinel Node Clinical Trials?  
David Krag, MD
9:25  Targeted Axillary Dissection for Breast Cancer: Less is More, Henry M. Kuerer, MD, PhD
9:45  Molecular Heterogeneity of Breast Cancer in Different Racial Groups, 
Lisa A. Newman, MD, MPH
10:05  Biology and Treatment of Metastatic Breast Cancer Based on Positive Clinical Trials,  
Hope S. Rugo, MD
10:25  Q&A Panel Discussion

10:35-11:05  Coffee Break - Visit the Exhibit & e-Posters - Networking

11:10-12:20  Novel Frontiers in Detecting Cancer Metastasis (Non-CME), Session Co-Chairs: Leong/Kashani-Sabet

11:10  Navigating the immunological microenvironment, in situ, to uncover the hidden clues of cancer immunology, Edward C. Stack, PhD, PerkinElmer, Hopkinton, USA
11:30  MicroRNA, Title TBD, Daniel Pregibon, PhD, Abcam, Cambridge, USA
11:50  Cancer Neoantigens: Targets for Immunotherapy, Mojca Skoberne, PhD, Gritstone Oncology, Boston, USA
12:10  Q&A Discussion

12:20 - 13:30  Dual Immune Checkpoint Inhibition for the First Line Treatment of BRAF Wild Type and BRAF Mutant Metastatic Melanoma, Steven J. O'Day, MD, John Wayne Cancer Institute, Non-CME Lunch Session Sponsored by Bristol-Myers Squibb
13:35 - 15:05 **Advances in Cancer Treatment, Session Chairs, Kim/Chan**

- **13:35** Treatment of In-transit Metastatic Melanoma, Jonathan S. Zager, MD
- **14:55** Latest development in Targeted therapy in solid cancer, Kevin Kim, MD
- **14:15** Extended survival time correlates to immunological changes in circulating lymphocytes of patients with pancreatic cancer after NK cell-enriched cell therapy: A retrospective study, Akihiro Shimosaka, New City Osaki Clinic, Tokyo, Japan
- **14:35** Novel treatment for metastatic gynecological cancer based on new biology, John K. Chan, MD
- **14:55** Q&A Panel Discussion

15:05 **Molecular Imaging of Cancer Metastasis** (KEYNOTE), Sanjiv Sam Gambhir, MD, PhD

15:35 - 16:05 Coffee Break - Visit the Exhibits & e-Posters - Networking

16:10 - 17:20 **Translating the Promise of Academic Research into Reality: Industry - Regulatory - Academic -Foundation Town Hall Meeting**, Moderator: John V. Frangioni, MD, PhD, CEO of the Curadel Companies, Professor Emeritus, Harvard Medical School, Non-CME

What is being done to bridge the divide between research and the clinical practice of medicine? How can the findings of research conducted in academic medical centers become more accessible to physicians in their daily practice? Attendees will participate in an open discussion with panel members from the federal government, industry, academic institutions and patient advocacy organizations regarding the challenges to participating in clinical research as well as successfully translating study results into clinical practice.

**Confirmed Panelists:** Libero Marzella, MD, FDA, CDER (Regulatory); David R. Parkinson, MD, Essa Pharmaceuticals, Inc. (Industry); Sanjiv (Sam) Gambhir, MD, PhD, Stanford University (Academic); Mona Wan, MS, MBA, Office of Technology Licensing, Stanford University, (Technology Licensing)

17:20-17:50 **RealTime Personalized Molecular Medicine For Monitoring CTC In Melanoma Patients Receiving CheckPoint Inhibitors**, Dave S. B. Hoon, PhD, John Wayne Cancer Institute, Santa Monica, USA. This Non-CME session is sponsored by: Clearbridge BioMedics

17:50 - 18:20 **Immuno-Oncology: A CRO’s Perspective** (KEYNOTE), Jai Balkissoon, MD, FACS, Non-CME

18:20 - 18:40 The Laboratory Testing to Complement Immuno-Oncology Therapy for Melanoma, Thomas Moss, MD, Non-CME, sponsored by MT Group


18:40 - 19:15 Parallel Rapid Fire Oral Abstract Presentations - Tumor Microenvironment and Cancer Progression Session Non-CME GOLD RUSH BALLROOM
18:40 - 19:15 Parallel Rapid Fire Oral Abstract Presentations - Cancer Metastasis & Treatment Session Non-CME EMERALD BALLROOM
18:40 - 19:15 Parallel Rapid Fire Oral Abstract Presentations - Late-Breaking Session Non-CME OREGON BALLROOM

19:30 - 22:30 **GALA DINNER IN CHINA TOWN** Far East Café, 631 Grant Ave, San Francisco, Tel. +1 415-982-3245
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td><strong>Novel Technology for SLN Imaging, Non-CME Breakfast Session</strong>, Co-Chairs: John V. Frangioni, MD, PhD &amp; Alessandro Testori, MD, Sponsored by Curadel, LLC</td>
</tr>
<tr>
<td>7:30</td>
<td>New Innovations in the Molecular Imaging of Cancer, John Frangioni, MD, The Curadel Companies, Marlborough, USA</td>
</tr>
<tr>
<td>7:50</td>
<td>New Ultrasound Imaging Modalities for Sentinel Lymph Nodes, Russel Witte, PhD, University of Arizona, Tuscon, USA</td>
</tr>
<tr>
<td>8:10</td>
<td>Enhanced Intraoperative Detection of Sentinel Lymph Nodes, Alessandro Testori, MD, Istituto Europeo di Oncologia, Milano, Italy</td>
</tr>
<tr>
<td>8:30 - 10:00</td>
<td>PhysioTouch negative pressure treatment supports lymphedema and cancer survivor rehabilitation, LYMPHEDEMA SESSION WORKSHOP, COFFEE BREAK - TIME FOR VISITING THE LYMPHEDEMA COMPANY EXHIBITORS &amp; NETWORKING Sponsored by PhysioTouch - Pacific Ballroom</td>
</tr>
<tr>
<td>8:35 - 10:00</td>
<td>Advances in Treatment for Gastrointestinal &amp; Genitourinary Cancer based on Sentinel Lymph Node Biology, Session Co-Chairs: Saha / Wilson</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break - Visit the Exhibits &amp; e-Posters - Networking</td>
</tr>
<tr>
<td>10:35-12:20</td>
<td>PATIENT SUMMIT - Lymphedema Following Cancer Therapy: Treatment Controversies, Co-Chairs: Thiadens/ Bernas</td>
</tr>
<tr>
<td>10:35</td>
<td>Introduction to lymphedema, Saskia R.J. Thiadens, RN</td>
</tr>
<tr>
<td>10:45</td>
<td>Cancer-related lymphedema and incidence, Paula J. B. Stewart, MD, MS</td>
</tr>
<tr>
<td>11:00</td>
<td>Imaging techniques for the lymphatic system, Michael Bernas, MS</td>
</tr>
<tr>
<td>11:15</td>
<td>Genetics of cancer-related lymphedema, Betty Smoot, PT, DPTSc</td>
</tr>
<tr>
<td>11:30</td>
<td>Treatment and advocacy of cancer-related LE, Saskia R.J. Thiadens, RN</td>
</tr>
<tr>
<td>11:45</td>
<td>Surgical treatments for lymphedema, Jay Granzow, MD, MPH, FACS</td>
</tr>
<tr>
<td>12:05</td>
<td>Q&amp;A Panel Discussion</td>
</tr>
<tr>
<td>12:20-13:30</td>
<td>Industry Sponsored Lunch Session for Patient Summit/Lymphedema Following Cancer Therapy, Update on Lymphedema: Current Clinical Trials at Stanford, Stanley G. Rockson, MD, Stanford University, Stanford, USA. Non-CME sessions sponsored by Eiger BioPharmaceuticals, Inc.</td>
</tr>
<tr>
<td>12:20-13:30</td>
<td>Technology Evolution for Value-Based Healthcare Non-CME Lunch Session Sponsored by Varian Medical Systems, Session Chair: Baldassare Stea, MD, PhD, Speakers TBD</td>
</tr>
<tr>
<td>13:35-15:05</td>
<td>Radiotherapy of Cancer Session Co-Chairs: Abendroth/Stea</td>
</tr>
<tr>
<td>13:35</td>
<td>New Frontiers in Cancer Therapy: Combining Radiotherapy with Immunotherapy to Treat Cancer, Baldassare Stea, MD, PhD</td>
</tr>
<tr>
<td>13:55</td>
<td>Radiotherapy of Cancer: Adjuvant Approach, Roy E. Abendroth, MD</td>
</tr>
<tr>
<td>14:15</td>
<td>Radiotherapy for Oligometastatic Cancer, Charles C. Hsu, MD, PhD</td>
</tr>
<tr>
<td>14:35</td>
<td>New Frontiers in Treatment of Lung Cancer, Charles C. Hsu, MD, PhD</td>
</tr>
<tr>
<td>14:55</td>
<td>Q&amp;A Panel Discussion</td>
</tr>
</tbody>
</table>
Saturday, April 21, 2017 continued:

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td><strong>Trainee &amp; Young Investigator Awardee Oral Abstract Presentations</strong></td>
</tr>
</tbody>
</table>

15:05 1st Place Trainee: Intravital imaging of lymph node metastasis reveals its ability to contribute to distant metastasis, Pereira, Ethel, et al, [Presenter], (Edwin L. Steele Laboratories, Department of Radiation Oncology, MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, United States)

15:15 2nd Place Trainee: Nanoparticle to treat established lymph node metastasis and primary tumor, Adjei, Isaac, et al, [Presenter], (Department of Biomedical Engineering, University of Florida, Gainesville, United States | Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, United States)

15:25 3rd Place Trainee: Cutaneous Immune Factors and Regression of In-Transit/Lymphatic Melanoma After Intralvesional Injection of Bacille Calmette-Guerin, Jones, Maris, et al, [Presenter], (Division of Surgical Oncology, John Wayne Cancer Institute, Providence Saint John’s Health Center, Santa Monica, CA)

15:35 1st Place YI: Epigenetic alterations of spliceosome factors are associated with organ-specific melanoma metastasis, Marzese, Diego, et al, [Presenter], (Division of Translational Molecular Medicine, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, United States)

15:45 2nd Place YI: Innovations in Lymphatic Microsurgery - MLVA and FLA-LVSP: The Complete Treatment Package, Campisi, Corrado, et al, [Presenter], (Department of Plastic, Reconstructive & Aesthetic Surgery, Unit for Lymphatic Microsurgery, Salus Hospital, GVM Care & Research, Reggio Emilia, Italy)

15:55 3rd Place YI: Cryofluorescence Tomography for Single-Cell and Micron-Level of Analysis of Cancer Metastasis and the Lymphovascular System - Bridging the Microscopic/Mesoscopic Divide, Holt, Robert, et al, [Presenter], (inviCRO, LLC, Boston, United States)

16:05 Closing Remarks, Stanley Leong: A summary of the status of and future perspectives on the study and management of cancer metastasis as presented during the Congress, address any unanswered questions, and pose others for future consideration.

16:15 Adjourn

**Early Discounted Registration and Discounted Hotel Room Block until:**

March 26, 2017

[www.cancermetastasis.org](http://www.cancermetastasis.org)
Confirmed CME Faculty as of February 16, 2017

• Stanley P.L. Leong, MD, California Pacific Medical Center, San Francisco, USA, Symposium Co-Chair
• Jonathan S. Zager, MD, Moffitt Cancer Center, Tampa, USA, Symposium Co-Chair
• Roy E. Abendroth, MD, California Pacific Medical Center, San Francisco, USA
• Athena Aktipis, PhD, Arizona State University, Tempe, USA
• Charles M. Balch, MD, University of Texas MD Anderson Cancer Center, Houston, USA
• Michael J. Bernas, MS, University of Arizona, Tuscon, USA
• Marcus W. Bosenberg, PhD, Yale School of Medicine, New Haven, USA
• Corrado Caracò, MD, National Cancer Institute of Naples, Naples, Italy
• John K. Chan, MD, California Pacific Medical Center, San Francisco, USA
• Michael Dellinger, PhD, UT Southwestern Medical Center, Dallas, USA
• Mark B. Faries, MD, John Wayne Cancer Institute, Santa Monica, USA
• Sanjiv Sam Gambhir, MD, PhD, Stanford University School of Medicine, Stanford, USA
• Jay Granzow, MD, MPH, FACS, UCLA School of Medicine, Manhattan Beach, USA
• Dale Han, MD, Yale School of Medicine, New Haven, USA
• Dave S. B. Hoon, PhD, John Wayne Cancer Institute, Santa Monica, USA
• Charles C. Hsu, MD, PhD, University of Arizona, Tucson, USA
• Mohammed Kashani-Sabet, MD, California Pacific Medical Center, San Francisco, USA
• Dontscho Kerjaschki, MD, Medical University of Vienna, Vienna, Austria
• Kevin Kim, MD, California Pacific Medical Center, San Francisco, USA
• Henry M. Kuerer, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, USA
• David Krag, MD, University of Vermont, Burlington, USA
• Carlo C. Maley, PhD, Arizona State University, Tempe, USA
• Donald M. McDonald, MD, PhD, University of California, San Francisco, USA
• Nobel Laureate W.E. Moerner, PhD, Stanford University, Stanford, USA
• S. David Nathanson, MD, Henry Ford Health System, Detroit, USA
• Lisa A. Newman, MD, MPH, Henry Ford Health System, Detroit, USA
• Barbara Pockaj, MD, Mayo Clinic, Phoenix, USA
• Douglas S. Reintgen, MD, University of South Florida, Tampa, USA
• Hope S. Rugo, MD, University of California San Francisco, San Francisco, USA
• Sukamal Saha, MD, Easton Hospital, Easton, USA
• Betty Smoot, PT, DPTSc, UCSF, San Francisco, USA
• Baldassarre Stea, MD, PhD, University of Arizona, Tuscon, USA
• Paula J. B. Stewart, MD, MS, Lakeshore Rehabilitation Hospital, Birmingham, USA
• Hiroya Takeuchi, MD, PhD, Keio University, Tokyo, Japan
• Saskia R.J. Thiadens, RN, Founder National Lymphedema Network, San Francisco, USA
• Richard L. White, Jr, MD, Carolinas HealthCare System, Charlotte, USA
• David Wiese, MD, PhD, McLaren Regional Medical Center, Flint, Michigan, USA
• Timothy G. Wilson, MD, John Wayne Cancer Center, Santa Monica, USA
• Marlys H. Witte, MD, University of Arizona, Tuscon, USA
• Russel Witte, PhD, University of Arizona, Tuscon, USA
• Isaac P. Witz, PhD, Tel Aviv University, Tel Aviv, Israel
Confirmed Non-CME Speakers as of March 17, 2017

- Jai Balkissoon, MD, FACS, PPD, Berkeley, USA
- John V. Frangioni, MD, PhD, The Curadel Companies, Marlborough, USA
- Eddy Hsueh, MD, Saint Louis University School of Medicine, St. Louis, USA
- Thomas Moss, MD, The MT Group, Los Angeles, USA
- Steven J. O'Day, MD, John Wayne Cancer Institute, Santa Monica, USA
- David R. Parkinson, MD, Essa Pharmaceuticals, Inc., Vancouver, Canada
- Daniel Pregibon, PhD, Abcam, Cambridge, USA
- Stanley G. Rockson, MD, Stanford University, Stanford, USA
- Mojca Skoberne, Ph.D, Gritstone Oncology, Boston, USA
- Edward C. Stack, PhD, PerkinElmer, Hopkinton, USA
- Alessandro Testori, MD, Istituto Europeo di Oncologia, Milano, Italy
- Mona Wan, MS, MBA, Stanford University, Stanford, USA
- Allison Welsh, PhD, Foundation Medicine Inc., Cambridge, USA

Cancer Metastasis through the Lymphovascular System: Biology & Treatment, 7th International Symposium is generously supported by the following organizations:

- CASTLE BIOSCIENCES INCORPORATED
- VA RIAN medical systems
- AMGEN
- FOUNDATION MEDICINE®
- Bristol-Myers Squibb
- Clearbridge BioMedics
Funding Statement
This activity is supported by educational grants from Eli Lilly and Pfizer.
Sponsorship
This activity is provided by:

CME Accreditation

Joint Providership Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and the Sentinel Node Oncology Foundation (SNOF). ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Academy for Continued Healthcare Learning designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This activity is intended for physicians specializing in surgery, oncology, molecular imaging, plastic surgery, radiation oncology, hematology, thoracic medicine with the remainder a mixture of predominately PhD/scientists from both academia and biotechnology as well as a smaller groups of attendees who are in training.

Learning Objectives

Upon completion of this activity, participants will be able to:

- Describe cancer initiation and progression in the tumor microenvironment.
- Distinguish the pathways of metastasis by virtue of the lymphatic versus vascular systems.
- Recognize the utility of SLN biopsy in multiple cancers and that SLN may be the primary gateway to cancer metastasis.
- Discuss the application of immune check point inhibition to treat cancer.
- Describe and integrate new genetic and mutational analysis information as biomarkers for diagnoses, staging and treatment selection for patients with metastatic cancers.
- Describe the potential application of molecular imaging for pinpoint stereotactic radiotherapy.
- Identify secondary lymphedema resulting from cancer treatment and methods to overcome lymphedema.

For more information: http://www.cancermetastasis.org/